Results 21 to 30 of about 28,652 (194)
Frontiers in Pharmacology, 2022 The present drug-drug interaction study investigates whether single or repeated doses of 240 mg Ginkgo biloba extract EGb 761® alter the pharmacokinetics or pharmacodynamics of rivaroxaban in healthy subjects.
Robert Hoerr +3 more
doaj +1 more source
Thromboprophylaxis for Children Post‐Fontan Procedure: Insights From the UNIVERSE Study
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021 Background Patients with single‐ventricle physiology who undergo the Fontan procedure are at risk for thrombotic events associated with significant morbidity and mortality.
Brian W. McCrindle +12 more
doaj +1 more source
Rivaroxaban in atrial fibrillation
Vascular Health and Risk Management, 2012 Warfarin is the traditional therapeutic option available to manage thromboembolic risk in atrial fibrillation. The hemorrhagic risk with warfarin depends mainly on the international normalized ratio (INR). Data from randomized controlled trials show that patients have a therapeutic INR (2.00-3.00) only 61%-68% of the time while taking warfarin, and ...
Lucas San Miguel, Mariano Giorgi
openaire +4 more sources
BMC Cardiovascular Disorders, 2017 Background Rivaroxaban is an oral anticoagulant approved in the US for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF).
Faye L. Norby +7 more
doaj +1 more source
Cancer Research, Statistics, and Treatment, 2020 Cancer-associated thrombosis is a challenging problem when treating patients with cancer. It is recurrent and difficult to treat because of the increased risk of bleeding. Low-molecular-weight heparin is the standard of care for treating cancer-associated venous thromboembolism/pulmonary embolism (VTE/PE).
Anuj Gupta +6 more
openaire +3 more sources
Scientific Reports, 2017 Rivaroxaban is an oral direct factor Xa inhibitor approved for the treatment of stroke and systemic thromboembolism in patients with non-valvular atrial fibrillation. Despite its efficacy, rivaroxaban therapy results in adverse effects and complications,
Dan Yang +5 more
doaj +1 more source
BMC Pharmacology and Toxicology, 2020 Background Rivaroxaban, a novel oral anticoagulant drug, is widely used in clinical practice. There is no standardized laboratory monitoring for rivaroxaban, and its plasma concentration in Chinese patients with deep vein thrombosis is unclear.
Ying Li +4 more
doaj +1 more source
Rivaroxaban: A novel anticoagulant
Indian Journal of Medical Sciences, 2010 For more than 50 years, warfarin has single-handedly ruled the world of anti-coagulation without any competition, whatsoever! The anticoagulant was made available in 1940 and since then no other anti-coagulant has ever been able to match it in the clinical arena.
CL Nawal, Muzaffar Ali
openaire +3 more sources
Rivaroxaban for the Treatment of Pulmonary Embolism [PDF]
Advances in Therapy, 2013 With the advent of new oral anticoagulants (NOACs) for the treatment of deep-vein thrombosis (DVT) and/or pulmonary embolism (PE), a new era of oral anticoagulation for patients with venous thromboembolism (VTE) has begun. Rivaroxaban is the first NOAC to receive regulatory approval for the acute and continued treatment of DVT and PE, and for the ...
Peter Verhamme, Thomas Vanassche
openaire +3 more sources
Risk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with Warfarin
Gastroenterology Research and Practice, 2016 Introduction. The risk of gastrointestinal (GI) bleeding with rivaroxaban has not been studied extensively. The aim of our study was to assess this risk in comparison to warfarin. Methods.
Muhammed Sherid +7 more
doaj +1 more source